Drugs / GSK1440115
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01424280 | Aug → Nov 2011 | asthma | Accenture | Completed | No outcome recorded |
| Phase 1 | NCT01202214 | Sep 2010 → ? | asthma | Accenture | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1440115 | “GSK1440115 is a urotensin II receptor antagonist which is being developed for the treatment of asthma.” NCT01202214 ↗1“Single Dose Study of GSK1440115 in Patients With Asthma” NCT01424280 ↗ |
| Action | Inhibit | “urotensin II receptor antagonist” NCT01202214 ↗ |
| Route | Oral | “single and repeat oral doses of GSK1440115” NCT01202214 ↗ |